BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19372254)

  • 21. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
    Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
    Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
    Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
    Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
    Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
    Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia.
    Buxhofer-Ausch V; Wolf D; Sormann S; Forjan E; Schimetta W; Gisslinger B; Heibl S; Krauth MT; Thiele J; Ruckser R; Gisslinger H
    Eur J Haematol; 2021 Jan; 106(1):58-63. PubMed ID: 32909297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
    Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Dellacasa CM; Salmoiraghi S; Delaini F; Rambaldi A; Barbui T
    Exp Hematol; 2009 Sep; 37(9):1016-21. PubMed ID: 19559071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
    Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
    Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.
    Barbui T; Carobbio A; Finazzi G; Vannucchi AM; Barosi G; Antonioli E; Guglielmelli P; Pancrazzi A; Salmoiraghi S; Zilio P; Ottomano C; Marchioli R; Cuccovillo I; Bottazzi B; Mantovani A; Rambaldi A;
    Haematologica; 2011 Feb; 96(2):315-8. PubMed ID: 21173097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risk of thrombosis in essential thrombocythemia and polycythemia vera.
    Pearson TC
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):16-21. PubMed ID: 12096353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.
    Carobbio A; Finazzi G; Guerini V; Spinelli O; Delaini F; Marchioli R; Borrelli G; Rambaldi A; Barbui T
    Blood; 2007 Mar; 109(6):2310-3. PubMed ID: 17110452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current management strategies for polycythemia vera and essential thrombocythemia.
    Guglielmelli P; Vannucchi AM
    Blood Rev; 2020 Jul; 42():100714. PubMed ID: 32546373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.
    Buxhofer-Ausch V; Steurer M; Sormann S; Schloegl E; Schimetta W; Gisslinger B; Ruckser R; Gastl G; Gisslinger H
    Eur J Haematol; 2016 Dec; 97(6):511-516. PubMed ID: 27037858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia.
    Rajnics P; Kellner Á; Karádi É; Moizs M; Bödör C; Király PA; Marosvári D; Andrikovics H; Egyed M
    Leuk Res; 2016 Sep; 48():101-6. PubMed ID: 27161323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
    Falanga A; Marchetti M; Barbui T; Smith CW
    Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
    Ahlstrand E; Samuelsson J; Lindgren M; Pettersson H; Liljeholm M; Ravn-Landtblom A; Scheding S; Andréasson B
    Eur J Haematol; 2020 Mar; 104(3):271-278. PubMed ID: 31863513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.
    Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Ruggeri M; Rodeghiero F; Rambaldi A; Barbui T
    Blood; 2008 Oct; 112(8):3135-7. PubMed ID: 18587010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.
    Carobbio A; Ferrari A; Masciulli A; Ghirardi A; Barosi G; Barbui T
    Blood Adv; 2019 Jun; 3(11):1729-1737. PubMed ID: 31175128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.